

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
OMRF:004USSerial No.
10/028,741Applicant
Shinichiro Kurosawa
Deborah J. Stearns-KurosawaFiling Date:
December 20, 2001Group:
1646U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CEC	C20	Abraham <i>et al.</i> , "Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial," <i>JAMA</i> , 273(12):934-941, 1995.
	C21	Barthold, "'Muromics': genomics from the perspective of the laboratory mouse," <i>Comparative Medicine</i> , 52(3):206-223, 2002.
	C22	Coughlin, "Protease-activated receptors in vascular biology," <i>Thromb. Haemost.</i> , 86:296-307, 2001
	C23	Deitch, "Animal models of sepsis and shock: a review and lessons learned," <i>Shock</i> , 9(1):1-11, 1998.
	C24	Fiedler <i>et al.</i> , "Monoclonal antibody to tumor necrosis factor- α prevents lethal endotoxin sepsis in adult rhesus monkeys," <i>J. Lab. Clin. Med.</i> , 120:574-588, 1992.
	C25	Giudici <i>et al.</i> , "Antithrombin replacement in patients with sepsis and septic shock," <i>Haematologica</i> , 84:452-460, 1999.
	C26	Gu <i>et al.</i> "Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo," <i>Blood</i> , 95(5):1687-1693, 2000.
CEC	C27	Hinshaw <i>et al.</i> , "Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF α)," <i>Circulatory Shock</i> , 30:279-292, 1990.

25394606.1

EXAMINER:

Claus M. K.

DATE CONSIDERED:

2/8/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

List of Patents and Publications

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1Atty. Docket No.
OMRF:004USSerial No.
10/028,741Applicant
Shinichiro Kurosawa
Deborah J. Stearns-KurosawaFiling Date:
December 20, 2001Group:
1646

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CE	C28	McCloskey <i>et al.</i> , "Treatment of septic shock with human monoclonal antibody HA-1A," <i>Ann. Intern. Med.</i> , 121:1-5, 1994.
	C29	Minnema <i>et al.</i> , "Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with <i>Escherichia coli</i> ," <i>Blood</i> , 95(4):1117-1123, 2000.
	C30	Moayeri <i>et al.</i> , "Bacillus anthracis lethal toxin induces TNF- α -independent hypoxia-mediated toxicity in mice," <i>J. Clin. Invest.</i> , 112(5):670-682, 2003.
	C31	Taylor <i>et al.</i> , "Antithrombin-III prevents the lethal effects of <i>Escherichia coli</i> infusion in baboons," <i>Circulatory Shock</i> , 26:227-235, 1988.
	C32	Tracey <i>et al.</i> , "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664, 1987.
	C33	Tracey <i>et al.</i> , "Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog," <i>Surg., Gynec., Obst.</i> , 164:415-422, 1987.
	C34	Vincent <i>et al.</i> , "Clinical trials of immunomodulatory therapies in severe sepsis and septic shock," <i>CID</i> , 34:1084-1093, 2002.
CE	C35	Zeni <i>et al.</i> , "Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment," <i>Critical Care Medicine</i> , 25(7):1095-1110, 1997.

25394606.1

EXAMINER:

Chen M. K.

DATE CONSIDERED:

2/8/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)